Daily Bulletin

The Times Real Estate

.

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- First approved allogeneic cell therapy product globally for the treatment of CLI

- Developed by Stempeutics over a period of twelve years, breakthrough treatment designed to address root cause of the disease at an affordable cost

- Cipla to market and distribute the drug in India to provide patient access

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

MUMBAI, India, Aug. 21, 2020 /PRNewswire/...

Read more: Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to...

Business News

Sydney Pipe Relining: The Smarter Way to Restore Infrastructure

In large-scale construction and civil works, outdated or damaged pipelines can bring operations to a halt. At Revolution Pipe Relining, we understand that time is money—especially for remedial build...

Daily Bulletin - avatar Daily Bulletin

Teleperformance (TP) Business Insights Report Reveals Key Shifts in Consumer Behaviour

TP’s Business Insights report  into consumer behaviors and preferences, taking in more than 57,000 respondents across 19 sectors, is shedding new light on how evolving channel preferences are resh...

Daily Bulletin - avatar Daily Bulletin

Navigating the Ascent: Your Strategic Guide to Executive Job Search

The air at the executive level is different. The stakes are higher, the competition more intense, and the path to your next leadership role requires a nuanced and strategic approach. Unlike more jun...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals